Redpoint Investment Management Pty LTD Bei Gene, Ltd. Transaction History

Redpoint Investment Management Pty LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 19, 2022	SELL	$248.56 - $389.34 $76,805 - $120,306	-309 Reduced 19.92%	1,242 $336,000
Q2 2021 Aug 05, 2021	BUY	$292.75 - $367.01 $454,055 - $569,232	1,551 New	1,551 $532,000
Q1 2021 Apr 13, 2021	SELL	$260.64 - $382.12 $321,629 - $471,536	-1,234 Closed	0 $0
Q4 2020 Jan 13, 2021	BUY	$221.31 - $316.61 $273,096 - $390,696	1,234 New	1,234 $319,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Redpoint Investment Management Pty LTD, based on Form 13F filings with the SEC.

Stay updated on Redpoint Investment Management Pty LTD with notifications on news.